Silencing Alters Gene Expression Signatures in Bladder Cancer Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 May 20

PMID 28521404

Citations 4

Authors

Jimin Chen

Nan Zhang

Jiaming Wen

Zhewei Zhang

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to identify the differentially expressed genes (DEGs) that are induced by the silencing of transforming growth factor-β-activated kinase 1 () in bladder cancer cells and to analyze the potential biological effects. Dataset GSE52452 from mutant fibroblast growth factor receptor 3 () bladder cancer cells transfected with control siRNA or -specific siRNA was downloaded from Gene Expression Omnibus. The DEGs between the two groups were identified using Limma package following data pre-processing by Affy in Bioconductor. Enrichment analysis of DEGs was performed using the Database for Annotation, Visualization and Integrated Discovery, followed by functional annotation using TRANSFAC, TSGene and TAG databases. Integrated networks were constructed by Cytoscape and sub-networks were extracted employing BioNet, followed by enrichment analysis of DEGs in the sub-network. A total of 43 downregulated and 21 upregulated genes were obtained. The downregulated genes were enriched in five pathways, including NOD-like receptor signaling pathway and functions related to cellular response. The upregulated genes were associated with cellular developmental processes. Transcription factor and 9 tumor-associated genes were screened from the DEGs. Among the DEGs, 10 hub nodes may represent important roles in the complex metabolic network, including , , , , , , , , and . Additionally, was correlated with , and , and these were enriched in signaling pathway and various cancer-associated pathways. Silencing may decrease cellular response to chemical stimulus via downregulating , , , , and ; increase cancer cell development via upregulating , and ; and regulate cancer metastasis through , , and .

Citing Articles

KCND2: A prognostic biomarker and regulator of immune function in gastric cancer.

Zhou H, Su D, Chen Y, Zhang Y, Huang P Cancer Med. 2023; 12(15):16279-16294.

PMID: 37347147 PMC: 10469724. DOI: 10.1002/cam4.6236.

Network-Based Analysis of Cognitive Impairment and Memory Deficits from Transcriptome Data.

Emanetci E, Cakir T J Mol Neurosci. 2021; 71(11):2415-2428.

PMID: 33713319 DOI: 10.1007/s12031-021-01807-9.

A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.

Wu X, Lv D, Cai C, Zhao Z, Wang M, Chen W Front Immunol. 2021; 11:590618.

PMID: 33391264 PMC: 7774015. DOI: 10.3389/fimmu.2020.590618.

Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder, prostate, kidney cancers.

Polo A, Marchese S, de Petro G, Montella M, Ciliberto G, Budillon A Sci Rep. 2018; 8(1):10395.

PMID: 29991691 PMC: 6039466. DOI: 10.1038/s41598-018-28739-6.

References

Tomlinson D, Baldo O, Harnden P, Knowles M . FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007; 213(1):91-8. PMC: 2443273. DOI: 10.1002/path.2207. View

Folini M, Pennati M, Zaffaroni N . RNA interference-mediated validation of genes involved in telomere maintenance and evasion of apoptosis as cancer therapeutic targets. Methods Mol Biol. 2009; 487:303-30. DOI: 10.1007/978-1-60327-547-7_15. View

Chadalapaka G, Jutooru I, Burghardt R, Safe S . Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res. 2010; 8(5):739-50. PMC: 2872686. DOI: 10.1158/1541-7786.MCR-09-0493. View

Boorjian S, Tickoo S, Mongan N, Yu H, Bok D, Rando R . Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer. Clin Cancer Res. 2004; 10(10):3429-37. DOI: 10.1158/1078-0432.CCR-03-0756. View

Nebert D, Dalton T . The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006; 6(12):947-60. DOI: 10.1038/nrc2015. View

McCarthy N . Bladder cancer: seemingly similar. Nat Rev Cancer. 2014; 14(4):214-5. DOI: 10.1038/nrc3704. View

Tomlinson D, Hurst C, Knowles M . Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene. 2007; 26(40):5889-99. PMC: 2443272. DOI: 10.1038/sj.onc.1210399. View

Karashima T, Sweeney P, Kamat A, Huang S, Kim S, Bar-Eli M . Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res. 2003; 9(7):2786-97. View

Altermann E, Klaenhammer T . PathwayVoyager: pathway mapping using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. BMC Genomics. 2005; 6:60. PMC: 1112592. DOI: 10.1186/1471-2164-6-60. View

10.

Barrett T, Edgar R . Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol. 2006; 411:352-69. PMC: 1619900. DOI: 10.1016/S0076-6879(06)11019-8. View

11.

Fritz J, Ferrero R, Philpott D, Girardin S . Nod-like proteins in immunity, inflammation and disease. Nat Immunol. 2006; 7(12):1250-7. DOI: 10.1038/ni1412. View

12.

Boehning D, Patterson R, Sedaghat L, Glebova N, Kurosaki T, Snyder S . Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat Cell Biol. 2003; 5(12):1051-61. DOI: 10.1038/ncb1063. View

13.

Cheng L, Lin H, Hu Y, Wang J, Yang Z . Gene function prediction based on the Gene Ontology hierarchical structure. PLoS One. 2014; 9(9):e107187. PMC: 4156439. DOI: 10.1371/journal.pone.0107187. View

14.

Zheng L, Pu J, Jiang G, Weng M, He J, Mei H . Abnormal expression of early growth response 1 in gastric cancer: association with tumor invasion, metastasis and heparanase transcription. Pathol Int. 2010; 60(4):268-77. DOI: 10.1111/j.1440-1827.2010.02512.x. View

15.

Urosevic J, Garcia-Albeniz X, Planet E, Real S, Cespedes M, Guiu M . Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat Cell Biol. 2014; 16(7):685-94. DOI: 10.1038/ncb2977. View

16.

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View

17.

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J . Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011; 3(99):99ra86. PMC: 3268675. DOI: 10.1126/scitranslmed.3002442. View

18.

Reynolds A, Leake D, Boese Q, Scaringe S, Marshall W, Khvorova A . Rational siRNA design for RNA interference. Nat Biotechnol. 2004; 22(3):326-30. DOI: 10.1038/nbt936. View

19.

Nicholson R, Gee J, Harper M . EGFR and cancer prognosis. Eur J Cancer. 2001; 37 Suppl 4:S9-15. DOI: 10.1016/s0959-8049(01)00231-3. View

20.

Gautier L, Cope L, Bolstad B, Irizarry R . affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3):307-15. DOI: 10.1093/bioinformatics/btg405. View